Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease

Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2014-07, Vol.10 (3), p.752
Main Authors: Bhamare, Sulabhchandra, Prabhakar, Pimparkar, Dharmadhikari, Aniruddha, Dedeepiya, Vidyasagar Devaprasad, Terunuma, Hiroshi, Senthilkumar, Rajappa, Srinivasan, Thangavelu, Reena, Helen C, Preethy, Senthilkumar, Abraham, Samuel J K
Format: Article
Language:English
Subjects:
Adoptive Transfer
Bladder cancer
Care and treatment
Case studies
Combined Modality Therapy
Diagnosis
Female
Gallbladder cancer
Gallbladder Neoplasms - diagnosis
Gallbladder Neoplasms - immunology
Gallbladder Neoplasms - pathology
Gallbladder Neoplasms - therapy
Humans
Immunotherapy
Killer Cells, Natural - immunology
Methods
Middle Aged
T-Lymphocytes - immunology
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c507t-8f298da89fdf6b863c4b1b5a7fd819c8e13eaa55f2a0fd404e829fd95df47ce73
cites
container_end_page
container_issue 3
container_start_page 752
container_title Journal of cancer research and therapeutics
container_volume 10
creator Bhamare, Sulabhchandra
Prabhakar, Pimparkar
Dharmadhikari, Aniruddha
Dedeepiya, Vidyasagar Devaprasad
Terunuma, Hiroshi
Senthilkumar, Rajappa
Srinivasan, Thangavelu
Reena, Helen C
Preethy, Senthilkumar
Abraham, Samuel J K
description Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.
doi_str_mv 10.4103/0973-1482.136048
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1620030516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A392470620</galeid><sourcerecordid>A392470620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-8f298da89fdf6b863c4b1b5a7fd819c8e13eaa55f2a0fd404e829fd95df47ce73</originalsourceid><addsrcrecordid>eNptkk2LHCEQhiUkZCeb3HMKQs498aO7tY_Dko-FhVySXMXWssfF1ol2B-b37B-Nw-xuCAwexPJ537KsQug9JduWEv6JDII3tJVsS3lPWvkCbegwyKalXL5Em-frK_SmlHtCOsGYfI2uWMcpF6LfoIfduqSQprQW7Od5jYAh7nU0MENc8LKHrA9H7CPW2OgCODk86RDwGLS1kGuwshmXRU-Ab39h7ZbTcc2TNzrgDAXM4lPVR4vNHub05Hn0EKyPU3Wu6jEAjik2h5ymKir-D2DrC9Scb9Erp0OBd4_7Nfr55fOPm2_N3fevtze7u8Z0RCyNdGyQVsvBWdePsuemHenYaeGspIORQDlo3XWOaeJsS1qQrLJDZ10rDAh-jT6efesbfq9QFnWf1hxrSkV7RggnHe3_UfUbQPno0pK1mX0xascH1gpS2Uo1F6gJYq09pAjO1_B__PYCX5eF2ZuLAnIWmJxKyeDUIftZ56OiRJ2GQ526r07dV-fhqJIPj_Wt4wz2WfA0DfwvOXC2Mw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1620030516</pqid></control><display><type>article</type><title>Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease</title><source>Publicly Available Content Database (ProQuest Open Access資料庫)</source><source>IngentaConnect Journals</source><creator>Bhamare, Sulabhchandra ; Prabhakar, Pimparkar ; Dharmadhikari, Aniruddha ; Dedeepiya, Vidyasagar Devaprasad ; Terunuma, Hiroshi ; Senthilkumar, Rajappa ; Srinivasan, Thangavelu ; Reena, Helen C ; Preethy, Senthilkumar ; Abraham, Samuel J K</creator><creatorcontrib>Bhamare, Sulabhchandra ; Prabhakar, Pimparkar ; Dharmadhikari, Aniruddha ; Dedeepiya, Vidyasagar Devaprasad ; Terunuma, Hiroshi ; Senthilkumar, Rajappa ; Srinivasan, Thangavelu ; Reena, Helen C ; Preethy, Senthilkumar ; Abraham, Samuel J K</creatorcontrib><description>Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/0973-1482.136048</identifier><identifier>PMID: 25313776</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Adoptive Transfer ; Bladder cancer ; Care and treatment ; Case studies ; Combined Modality Therapy ; Diagnosis ; Female ; Gallbladder cancer ; Gallbladder Neoplasms - diagnosis ; Gallbladder Neoplasms - immunology ; Gallbladder Neoplasms - pathology ; Gallbladder Neoplasms - therapy ; Humans ; Immunotherapy ; Killer Cells, Natural - immunology ; Methods ; Middle Aged ; T-Lymphocytes - immunology ; Treatment Outcome</subject><ispartof>Journal of cancer research and therapeutics, 2014-07, Vol.10 (3), p.752</ispartof><rights>COPYRIGHT 2014 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications &amp; Media Pvt Ltd Jul-Sep 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-8f298da89fdf6b863c4b1b5a7fd819c8e13eaa55f2a0fd404e829fd95df47ce73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1620030516?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25313776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bhamare, Sulabhchandra</creatorcontrib><creatorcontrib>Prabhakar, Pimparkar</creatorcontrib><creatorcontrib>Dharmadhikari, Aniruddha</creatorcontrib><creatorcontrib>Dedeepiya, Vidyasagar Devaprasad</creatorcontrib><creatorcontrib>Terunuma, Hiroshi</creatorcontrib><creatorcontrib>Senthilkumar, Rajappa</creatorcontrib><creatorcontrib>Srinivasan, Thangavelu</creatorcontrib><creatorcontrib>Reena, Helen C</creatorcontrib><creatorcontrib>Preethy, Senthilkumar</creatorcontrib><creatorcontrib>Abraham, Samuel J K</creatorcontrib><title>Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.</description><subject>Adoptive Transfer</subject><subject>Bladder cancer</subject><subject>Care and treatment</subject><subject>Case studies</subject><subject>Combined Modality Therapy</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Gallbladder cancer</subject><subject>Gallbladder Neoplasms - diagnosis</subject><subject>Gallbladder Neoplasms - immunology</subject><subject>Gallbladder Neoplasms - pathology</subject><subject>Gallbladder Neoplasms - therapy</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Killer Cells, Natural - immunology</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>T-Lymphocytes - immunology</subject><subject>Treatment Outcome</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkk2LHCEQhiUkZCeb3HMKQs498aO7tY_Dko-FhVySXMXWssfF1ol2B-b37B-Nw-xuCAwexPJ537KsQug9JduWEv6JDII3tJVsS3lPWvkCbegwyKalXL5Em-frK_SmlHtCOsGYfI2uWMcpF6LfoIfduqSQprQW7Od5jYAh7nU0MENc8LKHrA9H7CPW2OgCODk86RDwGLS1kGuwshmXRU-Ab39h7ZbTcc2TNzrgDAXM4lPVR4vNHub05Hn0EKyPU3Wu6jEAjik2h5ymKir-D2DrC9Scb9Erp0OBd4_7Nfr55fOPm2_N3fevtze7u8Z0RCyNdGyQVsvBWdePsuemHenYaeGspIORQDlo3XWOaeJsS1qQrLJDZ10rDAh-jT6efesbfq9QFnWf1hxrSkV7RggnHe3_UfUbQPno0pK1mX0xascH1gpS2Uo1F6gJYq09pAjO1_B__PYCX5eF2ZuLAnIWmJxKyeDUIftZ56OiRJ2GQ526r07dV-fhqJIPj_Wt4wz2WfA0DfwvOXC2Mw</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Bhamare, Sulabhchandra</creator><creator>Prabhakar, Pimparkar</creator><creator>Dharmadhikari, Aniruddha</creator><creator>Dedeepiya, Vidyasagar Devaprasad</creator><creator>Terunuma, Hiroshi</creator><creator>Senthilkumar, Rajappa</creator><creator>Srinivasan, Thangavelu</creator><creator>Reena, Helen C</creator><creator>Preethy, Senthilkumar</creator><creator>Abraham, Samuel J K</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20140701</creationdate><title>Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease</title><author>Bhamare, Sulabhchandra ; Prabhakar, Pimparkar ; Dharmadhikari, Aniruddha ; Dedeepiya, Vidyasagar Devaprasad ; Terunuma, Hiroshi ; Senthilkumar, Rajappa ; Srinivasan, Thangavelu ; Reena, Helen C ; Preethy, Senthilkumar ; Abraham, Samuel J K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-8f298da89fdf6b863c4b1b5a7fd819c8e13eaa55f2a0fd404e829fd95df47ce73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adoptive Transfer</topic><topic>Bladder cancer</topic><topic>Care and treatment</topic><topic>Case studies</topic><topic>Combined Modality Therapy</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Gallbladder cancer</topic><topic>Gallbladder Neoplasms - diagnosis</topic><topic>Gallbladder Neoplasms - immunology</topic><topic>Gallbladder Neoplasms - pathology</topic><topic>Gallbladder Neoplasms - therapy</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Killer Cells, Natural - immunology</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>T-Lymphocytes - immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bhamare, Sulabhchandra</creatorcontrib><creatorcontrib>Prabhakar, Pimparkar</creatorcontrib><creatorcontrib>Dharmadhikari, Aniruddha</creatorcontrib><creatorcontrib>Dedeepiya, Vidyasagar Devaprasad</creatorcontrib><creatorcontrib>Terunuma, Hiroshi</creatorcontrib><creatorcontrib>Senthilkumar, Rajappa</creatorcontrib><creatorcontrib>Srinivasan, Thangavelu</creatorcontrib><creatorcontrib>Reena, Helen C</creatorcontrib><creatorcontrib>Preethy, Senthilkumar</creatorcontrib><creatorcontrib>Abraham, Samuel J K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (ProQuest Open Access資料庫)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bhamare, Sulabhchandra</au><au>Prabhakar, Pimparkar</au><au>Dharmadhikari, Aniruddha</au><au>Dedeepiya, Vidyasagar Devaprasad</au><au>Terunuma, Hiroshi</au><au>Senthilkumar, Rajappa</au><au>Srinivasan, Thangavelu</au><au>Reena, Helen C</au><au>Preethy, Senthilkumar</au><au>Abraham, Samuel J K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>10</volume><issue>3</issue><spage>752</spage><pages>752-</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Advanced gall bladder cancer generally has a poor prognosis and also shows decreased response to conventional therapies like chemotherapy and radiotherapy. Though surgical resection is the most common approach followed, the 1-year survival rate is only 10%. Herein, we report the outcome of administration of autologous natural killer cell and activated T lymphocyte-based autologous immune enhancement therapy (AIET) in a case of gall bladder cancer stage IV which was progressing in spite of surgical resection and several sittings of chemotherapy. There were no adverse reactions after AIET. After three infusions of AIET, an improvement of the quality of life and general condition which is sustaining for more than 6 months and a substantial decrease in the CA 19-9 marker levels from 2938.22 U/mL before AIET to 511 U/mL, 5 months after AIET, in our experience make us recommend AIET along with other conventional treatments in similar cases.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>25313776</pmid><doi>10.4103/0973-1482.136048</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1482
ispartof Journal of cancer research and therapeutics, 2014-07, Vol.10 (3), p.752
issn 0973-1482
1998-4138
language eng
recordid cdi_proquest_journals_1620030516
source Publicly Available Content Database (ProQuest Open Access資料庫); IngentaConnect Journals
subjects Adoptive Transfer
Bladder cancer
Care and treatment
Case studies
Combined Modality Therapy
Diagnosis
Female
Gallbladder cancer
Gallbladder Neoplasms - diagnosis
Gallbladder Neoplasms - immunology
Gallbladder Neoplasms - pathology
Gallbladder Neoplasms - therapy
Humans
Immunotherapy
Killer Cells, Natural - immunology
Methods
Middle Aged
T-Lymphocytes - immunology
Treatment Outcome
title Autologous immune enhancement therapy in a case of gall bladder cancer stage IV after surgical resection and chemotherapy yielding a stable non-progressive disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A05%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autologous%20immune%20enhancement%20therapy%20in%20a%20case%20of%20gall%20bladder%20cancer%20stage%20IV%20after%20surgical%20resection%20and%20chemotherapy%20yielding%20a%20stable%20non-progressive%20disease&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Bhamare,%20Sulabhchandra&rft.date=2014-07-01&rft.volume=10&rft.issue=3&rft.spage=752&rft.pages=752-&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/0973-1482.136048&rft_dat=%3Cgale_proqu%3EA392470620%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c507t-8f298da89fdf6b863c4b1b5a7fd819c8e13eaa55f2a0fd404e829fd95df47ce73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1620030516&rft_id=info:pmid/25313776&rft_galeid=A392470620&rfr_iscdi=true